VBI Vaccines Inc.

Kronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin

Brii Biosciences is expanding the scope of its license for an investigational hepatitis B virus (HBV) immunotherapy drug and taking on an HBV vaccine in its more than four-year-old partnership with